Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen's Association

Company Overview - Alnylam Pharmaceuticals is a leading company in RNA interference (RNAi) therapeutics, aiming to transform the lives of patients with rare and prevalent diseases through innovative medicines [5][6] - The company has developed several commercial RNAi therapeutic products, including ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran) [5] - Alnylam is executing its "Alnylam P5x25" strategy to deliver transformative medicines while maintaining exceptional financial performance, establishing a strong position in the biotech industry [6] Leadership Recognition - Yvonne Greenstreet, CEO of Alnylam, has been named the 2024 Woman of the Year by the Healthcare Businesswomen's Association (HBA) for her extraordinary contributions to healthcare and women's advancement in the workplace [1][2] - Under Yvonne's leadership, Alnylam has been recognized as a socially responsible company and an exceptional workplace, earning accolades such as being listed among Fortune's Best Workplaces for Women and the Bloomberg Gender Equality Index [2][3] Leadership Background - Yvonne Greenstreet has over three decades of experience in the biopharmaceutical industry, having held significant positions at Pfizer and GlaxoSmithKline prior to joining Alnylam [3][4] - She has a medical degree from The University of Leeds and an MBA from INSEAD Business School, showcasing her strong educational background [4]